@article{70935e00c7dc439486088d05bada1283,
title = "Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans",
abstract = "Aims: African-American carriers of the transthyretin (TTR) valine-to-isoleucine substitution (V122I) are at increased risk of heart failure, yet many have relatively subtle abnormalities of left ventricular (LV) function. We sought to explore the influence of this mutation on left atrial (LA) structure and function in this population. Methods and results: We assessed 1225 genotyped African-Americans (age range, 67–89 years) participating in the Atherosclerosis Risk in Communities study who underwent echocardiography and were in sinus rhythm at study Visit 5 (2011 to 2013). Six LA parameters [LA maximum/minimum volume index, ejection fraction, and LA reservoir, conduit, and contractile longitudinal strains (LS)] were compared between V122I TTR variant carriers (n = 46) and non-carriers (n = 1179). LA minimum volume index was significantly greater and LA contractile LS was worse in carriers than non-carriers (19.5 ± 10.6 mL/m2 vs. 16.3 ± 8.4 mL/m2; 15.0 ± 5.8% vs. 16.8 ± 5.7%, respectively, both P < 0.05). Carriers had a significantly higher number of LA abnormalities than non-carriers (1.8 ± 2.2 vs. 1.1 ± 1.6, P = 0.009). The number of subjects with at least four LA abnormalities was significantly increased among carriers compared with non-carriers (27% vs. 12%; odds ratio 2.43; 95% confidence interval 1.06–5.58 after adjusting for age, sex, body mass index, and LV wall thickness and global LS). Conclusions: Left atrial enlargement and dysfunction were common in V122I TTR carriers with sinus rhythm than non-carriers, suggesting that abnormalities of LA function may represent early markers of subclinical disease in these individuals.",
keywords = "Cardiac amyloidosis, Echocardiography, Left atrium",
author = "Masatoshi Minamisawa and Inciardi, {Riccardo M.} and Brian Claggett and Cuddy, {Sarah A.M.} and Quarta, {Candida C.} and Shah, {Amil M.} and Sharmila Dorbala and Falk, {Rodney H.} and Kunihiro Matsushita and Kitzman, {Dalane W.} and Chen, {Lin Y.} and Solomon, {Scott D.}",
note = "Funding Information: : M.M. has received support from the Japanese Circulation Society, the Japanese Society of Echocardiography, and the Uehara Memorial Foundation Overseas Research Fellowship. S.A.M.C. has received research grants from Pfizer. A.M.S. has received research support from Novartis and Philips Ultrasound through Brigham and Women's Hospital and has consulted for Philips Ultrasound. S.D. has received research grants and honoraria from Pfizer and GE Health care. D.W.K. has received honoraria outside the present study as a consultant for AbbVie, Bayer, Merck, Medtronic, Relypsa, Corvia Medical, Boehringer Ingelheim, NovoNordisk, AstraZeneca, and Novartis, and grant funding outside the present study from Novartis, Bayer, and AstraZeneca, and stock ownership in Gilead Sciences. S.D.S. has received research grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lone Star Heart, Mesoblast, MyoKardia, National Institutes of Health/National Heart, Lung, and Blood Institute, Novartis, Sanofi Pasteur, and Theracos; and has consulted for Akros, Alnylam, Amgen, AstraZeneca, Bayer, BMS, Cardior, Corvia, Cytokinetics, Gilead, GSK, Ironwood, Merck, Myokardia, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardurion, AoBiome, Janssen, Cardiac Dimensions, and Tenaya. All other authors have nothing to disclose. Conflict of interest Funding Information: The authors thank the staff and participants of the Atherosclerosis Risk in Communities (ARIC) study for their important contributions. The ARIC study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I). This study was also supported by R01HL141288 (Chen). Funding Information: The authors thank the staff and participants of the Atherosclerosis Risk in Communities (ARIC) study for their important contributions. The ARIC study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I). This study was also supported by R01HL141288 (Chen). Conflict of interest: M.M. has received support from the Japanese Circulation Society, the Japanese Society of Echocardiography, and the Uehara Memorial Foundation Overseas Research Fellowship. S.A.M.C. has received research grants from Pfizer. A.M.S. has received research support from Novartis and Philips Ultrasound through Brigham and Women's Hospital and has consulted for Philips Ultrasound. S.D. has received research grants and honoraria from Pfizer and GE Health care. D.W.K. has received honoraria outside the present study as a consultant for AbbVie, Bayer, Merck, Medtronic, Relypsa, Corvia Medical, Boehringer Ingelheim, NovoNordisk, AstraZeneca, and Novartis, and grant funding outside the present study from Novartis, Bayer, and AstraZeneca, and stock ownership in Gilead Sciences. S.D.S. has received research grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lone Star Heart, Mesoblast, MyoKardia, National Institutes of Health/National Heart, Lung, and Blood Institute, Novartis, Sanofi Pasteur, and Theracos; and has consulted for Akros, Alnylam, Amgen, AstraZeneca, Bayer, BMS, Cardior, Corvia, Cytokinetics, Gilead, GSK, Ironwood, Merck, Myokardia, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardurion, AoBiome, Janssen, Cardiac Dimensions, and Tenaya. All other authors have nothing to disclose. Publisher Copyright: {\textcopyright} 2021 European Society of Cardiology.",
year = "2021",
month = aug,
doi = "10.1002/ejhf.2200",
language = "English (US)",
volume = "23",
pages = "1290--1295",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "8",
}